2020
An integrated program of computer-presented and physical cognitive training exercises for children with attention-deficit/hyperactivity disorder
Wexler BE, Vitulano LA, Moore C, Katsovich L, Smith SD, Rush C, Grantz H, Dong J, Leckman JF. An integrated program of computer-presented and physical cognitive training exercises for children with attention-deficit/hyperactivity disorder. Psychological Medicine 2020, 51: 1524-1535. PMID: 32090720, DOI: 10.1017/s0033291720000288.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderExperimental medicine approachTAU groupMedicine approachHyperactivity disorderWeeks of treatmentCombined subtypeDiagnosis of ADHDClinical trial designHyperactive-impulsive subtypeAttention-deficit/hyperactivity disorderCross-over designDeficit hyperactivity disorderClinical improvementClinical symptomsRandomized crossCognitive dysfunctionCT groupPathophysiological heterogeneityCONSORT recommendationsTrial designResponse rateChange scoresSubtypesTargeted pathology
2003
A placebo-controlled trial of risperidone in Tourette syndrome
Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60: 1130-1135. PMID: 12682319, DOI: 10.1212/01.wnl.0000055434.39968.67.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsBody WeightChildDiagnostic Techniques, NeurologicalDopamine AntagonistsDose-Response Relationship, DrugDouble-Blind MethodErectile DysfunctionFemaleHeart Conduction SystemHumansMaleMiddle AgedPhobic DisordersRisperidoneSeverity of Illness IndexTicsTourette SyndromeTreatment OutcomeConceptsYale Global Tic Severity ScalePlacebo-controlled trialTotal tic scoreTourette syndromeTic scoreYGTSS total tic scoreCardiac conduction timesSafety of risperidonePrimary outcome measureWeeks of treatmentDurability of efficacyTic Severity ScaleShort-term treatmentMedication-free subjectsPlacebo patientsMedication discontinuationRisperidone groupExtrapyramidal symptomsTic symptomsOutcome measuresDose reductionConduction timeSeverity ScaleTic severityBody weight
2001
A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder
Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leckman JF. A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder. American Journal Of Psychiatry 2001, 158: 1067-1074. PMID: 11431228, DOI: 10.1176/appi.ajp.158.7.1067.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderWeeks of treatmentPlacebo groupTic disordersGuanfacine groupDeficit hyperactivity disorderClinical Global Improvement ScaleHyperactivity disorderSafety of guanfacineGlobal Improvement ScaleDouble-blind conditionsTreatment of childrenMedication-free subjectsDose adjustmentBlood pressureADHD Rating ScaleDisorders ClinicWeek 4Mean improvementEffective treatmentImprovement ScaleGuanfacinePlaceboTic severityContinuous Performance Test
1997
Fluoxetine Has No Marked Effect on Tic Symptoms in Patients with Tourette's Syndrome: A Double-Blind Placebo-Controlled Study
Scahill L, Riddle MA, King RA, Hardin MT, Rasmusson A, Makuch RW, Leckman JF. Fluoxetine Has No Marked Effect on Tic Symptoms in Patients with Tourette's Syndrome: A Double-Blind Placebo-Controlled Study. Journal Of Child And Adolescent Psychopharmacology 1997, 7: 75-85. PMID: 9334893, DOI: 10.1089/cap.1997.7.75.Peer-Reviewed Original ResearchConceptsTourette syndromeObsessive-compulsive symptomsObsessive-compulsive disorderPlacebo-controlled crossover trialTreatment of ticsWeeks of treatmentEfficacy of fluoxetineFluoxetine monotherapyFluoxetine treatmentCrossover trialObsessive-compulsive featuresAdditional subjectsFluoxetineSymptomsSignificant reductionSyndromeTreatmentSubjectsCrossover analysisMonotherapyPatientsMarked effectTrialsWeeks
1995
Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. The Journal Of Clinical Psychiatry 1995, 56: 526-8. PMID: 7592506.Peer-Reviewed Original ResearchConceptsSerotonin uptake inhibitorObsessive-compulsive disorderY-BOCS scoresYale-Brown Obsessive Compulsive ScaleRisperidone additionOCD patientsComorbid chronic tic disorderPatients' Y-BOCS scoresRefractory obsessive-compulsive disorderOpen-label mannerLow-dose haloperidolSide effect profileWeeks of treatmentChronic tic disorderEffective treatment strategiesObsessive Compulsive ScaleSUI treatmentEffect profileNeuroleptic treatmentTardive dyskinesiaTypical neurolepticsModerate sedationReceptor antagonistTic disordersTreatment strategies
1994
Haloperidol Addition in Fluvoxamine-Refractory Obsessive-Compulsive Disorder: A Double-blind, Placebo-Controlled Study in Patients With and Without Tics
McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol Addition in Fluvoxamine-Refractory Obsessive-Compulsive Disorder: A Double-blind, Placebo-Controlled Study in Patients With and Without Tics. JAMA Psychiatry 1994, 51: 302-308. PMID: 8161290, DOI: 10.1001/archpsyc.1994.03950040046006.Peer-Reviewed Original ResearchConceptsComorbid chronic tic disorderChronic tic disorderYale-Brown Obsessive Compulsive ScaleObsessive-compulsive disorderTic disordersFluvoxamine treatmentOCD patientsClinical Global Impression ScalePlacebo-treated groupDouble-blind fashionWeeks of treatmentGlobal Impression ScaleTreatment of patientsHaloperidol-treated groupEffective symptom reductionObsessive Compulsive ScaleNeuroleptic therapyBlood levelsImpression ScaleTreatment outcomesTreatment responseAdequate treatmentPatientsPlaceboSymptom reduction